Drug Trial Radar · NCT07318805
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Dec 23, 2025
Primary completion
Apr 14, 2029
Study completion Apr 14, 2030
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants that have advanced or metastatic breast cancer (BC), or advanced or metastatic colorectal cancer (CRC). All participants in this study will take the study medication (PF-08032562) as pill by mouth. This will be repeated for 28-day cycles. Depending on which part of the study participants are enrolled into, they will receive the study medication PF-08032562 alone or in combination with other anti-cancer medications. The study medication (PF-08032562) will be taken by mouth (PO) in combination with other anti-cancer medications given in the study clinic by intramuscular (IM) injection into the muscle or intravenous (IV) infusion that is directly injected into the veins at different times (depending on the treatment) during the 28-day cycle. The study may also test different schedules.
Conditions
- Advanced Breast Cancer
- Metastatic Breast Cancer (HR+/ HER2-)
- Colorectal Cancer
- Metastatic Colorectal Adenocarcinoma
- Triple Negative Breast Cancer
Interventions
PF-08032562Drug
Taken by mouth (PO)
FulvestrantDrug
Selective Estrogen Receptor Degrader (SERD)
CetuximabDrug
Monoclonal antibody (EGFR inhibitor)
FluorouracilDrug
Part of FOLFOX chemotherapy regimen cytotoxic chemotherapy (antimetabolite and pyrimidine analog)
OxaliplatinDrug
Part of FOLFOX chemotherapy regimen platinum based compound (alkylating agent)
LeucovorinDrug
Part of FOLFOX chemotherapy regimen (folic acid analog)
BevacizumabDrug
Monoclonal antibody (VEG-F inhibitor)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)Time frame: Baseline up to 28 days
- Part 1 (Dose Escalation): Number of participants with laboratory abnormalitiesTime frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
- Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
- Part 2 (Dose Expansion): Objective Response Rate (ORR)Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Locations
17 sites in 3 countries. Site status is shown where the registry gives one.
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California · Recruiting
START Midwest, LLC
Grand Rapids, Michigan · Recruiting
Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy
Long Island City, New York · Recruiting
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center 53rd street.
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York · Recruiting
The University of Texas MD Anderson Cancer Center - Conroe
Conroe, Texas · Recruiting
The University of Texas - M.D. Anderson Cancer Center
Houston, Texas · Recruiting
The University of Texas, MD Anderson Cancer Center - West Houston
Houston, Texas · Recruiting
The University of Texas, MD Anderson Cancer Center - League City
League City, Texas · Recruiting
START San Antonio
San Antonio, Texas · Recruiting
The University of Texas, MD Anderson Cancer Center - Sugar Land
Sugar Land, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
CHU Poitiers
Poitiers, France · Not yet recruiting
Gustave Roussy
Villejuif, Val-de-marne, France · Not yet recruiting
Hospital Universitario HM Sanchinarro
Madrid, Spain · Not yet recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [barcelona], Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.